#	Pagina
attuale pagina	/open-h2020/projects/196906/index.html

Opendata, web and dolomites

NEWCARBOVAX SIGNED

New generation of carbohydrate-based vaccines via rational understanding of their immunological mechanism

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

NEWCARBOVAX project word cloud

Explore the words cloud of the NEWCARBOVAX project. It provides you a very rough idea of what is the project "NEWCARBOVAX" about.

microbial demonstrated glycoconjugate gbsiii variables protective hypothesis optimized explanation peptides ed successful chemistry cell epitope therapeutics vaccine analysing activation model anchor immunological antigen risk presented mhc covalently strategies contrast suggests glycan immunogenicity clinical extend globally rational populations innovative basic random times mechanisms immune protein health immunogenic presenting conjugation antibody strategy cells carbohydrate class translational benefits peptide chemical conjugates mechanism mouse length disease empirically straightforward designed linking sugar generally light enormous linked conjugate generate receptor platform render presentation chain contribution vaccines carrier

Project "NEWCARBOVAX" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITA DEGLI STUDI DI MILANO Organization address address: Via Festa Del Perdono 7 city: MILANO postcode: 20122 website: www.unimi.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Project website	https://www.hms.harvard.edu/dms/bbs/fac/Kasper.php
Total cost	244˙269 €
EC max contribution	244˙269 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2014
Funding Scheme	MSCA-IF-GF
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2019-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITA DEGLI STUDI DI MILANO UNIVERSITA DEGLI STUDI DI MILANO Organization address address: Via Festa Del Perdono 7 city: MILANO postcode: 20122 website: www.unimi.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MILANO)	coordinator	244˙269.00
2	GLAXOSMITHKLINE VACCINES SRL GLAXOSMITHKLINE VACCINES SRL Organization address address: VIA FIORENTINA 1 city: SIENA postcode: 53100 website: www.novartis.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (SIENA)	participant	0.00
3	PRESIDENT AND FELLOWS OF HARVARD COLLEGE PRESIDENT AND FELLOWS OF HARVARD COLLEGE Organization address address: MASSACHUSETTS AVENUE 1350 city: CAMBRIDGE postcode: 2138 website: www.bidmc.harvard.edu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (CAMBRIDGE)	partner	0.00

Map

Project objective

Glycoconjugate vaccines have provided enormous health benefits globally, but they have been less successful in some populations at high risk for developing disease. They are composed by a sugar antigen covalently linked to a carrier protein. The traditional hypothesis of immune activation by glycoconjugate vaccines suggests that only peptides generated from glycoconjugate processing can be presented to and recognized by T cells, and this contribution is crucial for their immunogenicity. In most cases, conjugation processes have been set-up empirically. Recently, new findings offer a rational explanation for how conjugates work and may render vaccine development a more straightforward process. In contrast with the classical mechanism, this new model suggests that carbohydrate presentation to the T cell by antigen-presenting cell may strongly enhance antibody response. The key strategy is to conjugate the carbohydrate to peptides which anchor the conjugate via MHC class II and allow the sugar epitope to be presented via the T cell receptor. Application of this principle resulted in a GBSIII vaccine strongly protective in a mouse model and 50–100 times more immunogenic than a traditional vaccine composed by random linking of the sugar on a protein carrier. Although the principle has been demonstrated much remains to be done to generally apply the concept to generate vaccines for clinical use. In the proposed study, we will extend the approach by analysing different variables (peptide carrier, glycan chain length, conjugation chemistry and microbial antigen), with the aim of using the increased understanding of basic immunological mechanisms to develop a new translational platform for optimized and cost-effective carbohydrate-based vaccines. Innovative strategies of conjugation chemistry will be also evaluated to generate new therapeutics with chemical properties designed in light of specific information on antigen presentation.

Publications

List of publications.
year	authors and title	journal	last update
2019	Giuseppe Stefanetti, Nihal Okan, Avner Fink, Erica Gardner, Dennis L. Kasper Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies to Francisella tularensis published pages: 7062-7070, ISSN: 0027-8424, DOI: 10.1073/pnas.1900144116	Proceedings of the National Academy of Sciences 116/14	2020-02-28

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEWCARBOVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEWCARBOVAX" are provided by the European Opendata Portal: CORDIS opendata.